EditFrom NeuroLex
Propiomazine
| Name: | Propiomazine |
| Description: | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, propiomazine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors. Pharmacology: Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, propiomazine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors. Mechanism of action: Propiomazine is an antagonist at types 1, 2, and 4 dopamine receptors, serotonin (5-HT) receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Propiomazine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT2 receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Propiomazine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Drug type: Approved. Small Molecule. Drug category: Sedatives and Hypnotics |
| Synonym(s): | Largon, Phenoctyl, Propiomazina (INN-Spanish), Propiomazine (Usan:Ban:Inn), Propiomazinum (INN-Latin), Propionylpromethazine |
| Related to: | Cholinergic system, D(1A) dopamine receptor, Muscarinic acetylcholine receptor M3, Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M5, D(4) dopamine receptor, Muscarinic acetylcholine receptor M4, Histamine H1 receptor, 5-hydroxytryptamine 2A receptor, Alpha-1A adrenergic receptor, 5-hydroxytryptamine 2C receptor, Muscarinic acetylcholine receptor M2, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor, D(2) dopamine receptor |
| Has role: | Drug |
| Super-category: | Molecule |
| URL: | http://www.drugbank.ca/drugs/DB00777 |
| Id: | CHEBI: 8491 |
| Link to OWL / RDF: | Download this content as OWL/RDF |
Facts about PropiomazineRDF feed
| Comment | taken from DrugBank |
| CurationStatus | uncurated + |
| Curator | Ab + |
| DefiningCitation | http://www.drugbank.ca/drugs/DB00777 + |
| Definition | Propiomazine, an atypical antipsychotic ag … Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, propiomazine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors. Pharmacology: Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, propiomazine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors. Mechanism of action: Propiomazine is an antagonist at types 1, 2, and 4 dopamine receptors, serotonin (5-HT) receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Propiomazine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT2 receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Propiomazine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Drug type: Approved. Small Molecule. Drug category: Sedatives and Hypnotics le. Drug category: Sedatives and Hypnotics |
| Has role | Drug + |
| Id | CHEBI: 8491 + |
| Label | Propiomazine + |
| ModifiedDate | 29 October 2010 + |
| RelatedTo | Cholinergic system +, D(1A) dopamine receptor +, Muscarinic acetylcholine receptor M3 +, Muscarinic acetylcholine receptor M1 +, Muscarinic acetylcholine receptor M5 +, D(4) dopamine receptor +, Muscarinic acetylcholine receptor M4 +, Histamine H1 receptor +, 5-hydroxytryptamine 2A receptor +, Alpha-1A adrenergic receptor +, 5-hydroxytryptamine 2C receptor +, Muscarinic acetylcholine receptor M2 +, Alpha-1B adrenergic receptor +, Alpha-1D adrenergic receptor +, and D(2) dopamine receptor + |
| SuperCategory | Molecule + |
| Synonym | Largon +, Phenoctyl +, Propiomazina (INN-Spanish) +, Propiomazine (Usan:Ban:Inn) +, Propiomazinum (INN-Latin) +, and Propionylpromethazine + |